54
Participants
Start Date
April 25, 2025
Primary Completion Date
January 30, 2026
Study Completion Date
February 27, 2026
HL-400
Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.
Placebo
Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo.
RECRUITING
Pharmaron CPC, Inc., Baltimore
Lead Sponsor
Highlightll Pharmaceutical (USA) LLC
INDUSTRY